“Namzaric combines, in one capsule, two complementary therapeutic agents which are often co-prescribed as approximately 70% of Namenda XR patients are also on AChEI therapy.  Both Namenda XR and donepezil have proven efficacy and safety, for the treatment of moderate/severe Alzheimer’s disease.”

The finding may help scientists track down the mechanism that causes nearly all cases of Alzheimer’s, a mechanism that is not well understood.

Remarkably, this boost in cognition occurred despite the accumulation of Alzheimer-related toxins in the brain, such as amyloid-beta and tau.

This finding provides the most compelling evidence to date of brain inflammation, and more specifically microglial activation, in MDE. The correlation between higher ACC TSPO VT and the severity of MDE is consistent with the concept that neuroinflammation in specific regions may contribute to sickness behaviors that overlap with the symptoms of MDE.

Two UC San Diego Researchers to Lead Alzheimer’s Disease Cooperative Study.

Examining post-mortem tissue from the brains of people with Alzheimer’s disease, Stanford University School of Medicine investigators identified what appear to be iron-containing microglia in a particular part of the hippocampus, a key brain structure whose integrity is critical to memory formation.

Levels of neurogranin, a cerebrospinal fluid (CSF) biomarker for synaptic loss, were elevated in patients with Alzheimer’s disease (AD) compared with cognitively normal individuals. Neurogranin levels also predicted progression from mild cognitive impairment (MCI) to AD dementia, researchers reported here on Monday at the Alzheimer’s Association International Conference (AAIC).

The model developed by the three researchers Prof Markus Werning, Prof Sen Cheng and Prof Thomas Suddendorf differs from other approaches with regard to one major aspect: it suggests a new relationship between mental time travel and episodic memory.

Howard Feldman of University of British Columbia is known for seminal research in dementias; UC launches new $4 million Alzheimer’s disease initiative.

Nancy Reagan, the influential and stylish wife of the 40th president of the United States who unabashedly put Ronald Reagan at the center of her life but became a political figure in her own right, died on Sunday at her home in Los Angeles. She was 94.

Sponsored by the UC Office of the President with a foundational grant of $4 million, the UC Cures initiative invited hundreds of laboratories throughout the 10-campus system to find new answers to Alzheimer’s disease and related disorders.

A protein called Aβ is thought to cause neuronal death in Alzheimer’s disease (AD). Aβ forms insoluble aggregates in the brains of patients with AD, which are a hallmark of the disease. Aβ and its propensity for aggregation are widely viewed as intrinsically abnormal. However, in new work, Kumar et al. show that Aβ is…

Today the Senate Committee on Appropriations approved a bill that would boost U.S. government funding for Alzheimer’s disease to almost $1.4 billion in fiscal year 2017.

Researchers presenting at the Alzheimer’s Association International Conference 2016 (AAIC 2016) in Toronto introduced and described a new condition or patient status, known as Mild Behavioral Impairment (MBI), that may be a forerunner of neurodegeneration and progression to mild cognitive impairment (MCI) or dementia.

At the direction of Congress, the National Institutes of Health (NIH) develops an annual professional judgment budget to estimate the funds needed to fully pursue scientific opportunities to meet the research goal of the Plan—to effectively treat and prevent Alzheimer’s and related dementias by 2025.

Concerns over the Zika virus have focused on pregnant women due to mounting evidence that is causes brain abnormalities in developing fetuses. However, new research in mice suggests that certain adult brain cells may be vulnerable to infection as well.

No use soft-pedaling a hard truth: The year ended on a downer. Solanezumab—the therapeutic antibody in line to be the first approved AD drug in well over a decade—failed to significantly slow cognitive decline in people with mild AD and a positive amyloid scan/CSF Aβ profile.

We are thrilled to begin the New Year with over 50,000 participants in Brain Health Registry! We are grateful for your help in achieving this significant milestone, and cannot thank you enough for your efforts to help scientists better understand brain disease.

These concepts were approved at the National Advisory Council on Aging (NACA) meeting on January 18, 2017. We have posted the approved concepts here to give interested researchers maximal lead time to plan projects.

Inside NIA: An early-warning system for researchers